0.7188
+0.0189
+(2.70%)
At close: April 10 at 4:00:01 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.12 | -0.12 | -0.46 | -0.49 |
| Low Estimate | -0.13 | -0.14 | -0.56 | -0.66 |
| High Estimate | -0.12 | -0.09 | -0.36 | -0.31 |
| Year Ago EPS | -0.25 | -0.2 | -0.72 | -0.46 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 4 | 3 |
| Avg. Estimate | 901.5k | 1.4M | 6.62M | 6.24M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 1.8M | 2.79M | 9.75M | 10M |
| Year Ago Sales | 1.72M | 2.66M | 9.29M | 6.62M |
| Sales Growth (year/est) | -47.50% | -47.50% | -28.77% | -5.72% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.29 | -0.28 | -0.19 | -0.14 |
| EPS Actual | -0.25 | -0.2 | -0.17 | -0.13 |
| Difference | 0.04 | 0.08 | 0.02 | 0.02 |
| Surprise % | 14.53% | 28.57% | 10.03% | 11.72% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.12 | -0.12 | -0.46 | -0.49 |
| 7 Days Ago | -0.15 | -0.14 | -0.57 | -0.46 |
| 30 Days Ago | -0.15 | -0.14 | -0.57 | -0.46 |
| 60 Days Ago | -0.15 | -0.14 | -0.57 | -0.46 |
| 90 Days Ago | -0.15 | -0.14 | -0.57 | -0.46 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 2 | 2 | 1 |
| Up Last 30 Days | -- | 2 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CUE | 50.00% | 42.50% | 36.44% | -5.43% |
| S&P 500 | 6.43% | 6.13% | 9.43% | 14.26% |
Upgrades & Downgrades
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 4/2/2025 |
| Maintains | Stifel: Buy to Buy | 8/20/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 7/26/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 7/26/2024 |
| Maintains | Stifel: Buy to Buy | 4/9/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/9/2024 |
Related Tickers
RNTX Rein Therapeutics Inc.
1.5600
+7.59%
ACTU Actuate Therapeutics, Inc. Common stock
7.11
-3.72%
EXOZ eXoZymes, Inc.
11.77
+0.43%
COYA Coya Therapeutics, Inc.
4.9300
-5.92%
INAB IN8bio, Inc.
0.1471
-3.67%
APTO Aptose Biosciences Inc.
1.7100
0.00%
MOLN Molecular Partners AG
3.7900
+6.76%
TRVI Trevi Therapeutics, Inc.
5.28
-2.22%
LTRN Lantern Pharma Inc.
3.0400
+3.40%
DMAC DiaMedica Therapeutics Inc.
3.5100
-5.14%